You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Burkitt Lymphoma

Showing 76 - 100 of 5,429
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin Lymphoma Trial in Worldwide (Epcoritamab)

Recruiting
  • Non Hodgkin Lymphoma
  • Palo Alto, California
  • +44 more
Aug 12, 2022

Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic

Completed
Has Results
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • +115 more
  • Fludarabine Phosphate
  • +6 more
  • Denver, Colorado
  • +10 more
Oct 29, 2019

Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in

Completed
  • Acute Undifferentiated Leukemia
  • +63 more
  • total-body irradiation
  • +7 more
  • Seattle, Washington
  • +1 more
Jan 17, 2020

Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)

Completed
  • Chronic Myeloproliferative Disorders
  • +5 more
  • sargramostim
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2022

Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma Trial in Houston

Not yet recruiting
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +6 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 6, 2020

Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

Active, not recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • fractionated first dose rituximab
  • Geneva, Switzerland
    University Hospital Geneva
Apr 21, 2023

B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Loncastuximab Tesirine
  • +4 more
  • Pembroke Pines, Florida
  • +19 more
Jul 22, 2022

Lymphoma Trial in Stanford (rituximab)

Completed
  • Lymphoma
  • rituximab
  • Stanford, California
    Stanford University Medical Center
May 25, 2022

Lymphoma Trial in Duarte (drug, other, procedure)

Active, not recruiting
  • Lymphoma
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Duarte, California
  • +4 more
Dec 24, 2019

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic

Completed
  • Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
  • +76 more
  • fludarabine phosphate
  • +6 more
  • Tucson, Arizona
  • +10 more
Jan 17, 2020

Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

Recruiting
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Jan 25, 2023

Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit (3'-deoxy-3'-[18F]fluorothymidine)

Recruiting
  • Brain and Central Nervous System Tumors
  • +8 more
  • 3'-deoxy-3'-[18F]fluorothymidine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Mar 30, 2022

Lymphoid Malignancies Trial in United States (AVM0703)

Recruiting
  • Lymphoid Malignancies
  • Duarte, California
  • +6 more
Nov 14, 2022

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic

Completed
Has Results
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +99 more
  • fludarabine phosphate
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 30, 2019

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid

Completed
Has Results
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +99 more
  • alemtuzumab
  • +6 more
  • Denver, Colorado
  • +6 more
Jan 15, 2020

Lymphoma Trial in Duarte, South Pasadena (biological, drug, other)

Active, not recruiting
  • Lymphoma
  • rituximab
  • +3 more
  • Duarte, California
  • +1 more
Feb 28, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, CNS Lymphoma, Intraocular

Completed
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +5 more
  • Scottsdale, Arizona
  • +6 more
Jul 18, 2019

Hematologic Malignancies Trial in Minneapolis (Haplo HCT <55 years old, Haplo HCT =55 years old, GVHD Prophylaxis)

Recruiting
  • Hematologic Malignancies
  • Haplo HCT <55 years old
  • +4 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 25, 2023

Rituximab in Children With Blood Diseases

Not yet recruiting
  • Rituximab
  • +2 more
  • (no location specified)
Apr 8, 2022

Lymphoma Trial (pegfilgrastim, rituximab, cyclophosphamide)

Completed
  • Lymphoma
  • pegfilgrastim
  • +5 more
  • (no location specified)
Jul 2, 2021

Lymphoma, HIV Trial in United States (Autologous transplant, BCNU, Etoposide)

Completed
Has Results
  • Lymphoma
  • HIV
  • Autologous transplant
  • +4 more
  • Duarte, California
  • +15 more
Dec 6, 2022